These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20516552)

  • 1. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
    Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
    Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.
    Rossi R; Lichtner M; De Rosa A; Sauzullo I; Mengoni F; Massetti AP; Mastroianni CM; Vullo V
    Clin Exp Immunol; 2011 Nov; 166(2):184-90. PubMed ID: 21985364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
    Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor.
    Watson C; Jenkinson S; Kazmierski W; Kenakin T
    Mol Pharmacol; 2005 Apr; 67(4):1268-82. PubMed ID: 15644495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
    Nakata H; Steinberg SM; Koh Y; Maeda K; Takaoka Y; Tamamura H; Fujii N; Mitsuya H
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2111-9. PubMed ID: 18378711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells.
    Longden J; Cooke EL; Hill SJ
    Br J Pharmacol; 2008 Apr; 153(7):1513-27. PubMed ID: 18223665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
    Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
    Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
    Tilton JC; Amrine-Madsen H; Miamidian JL; Kitrinos KM; Pfaff J; Demarest JF; Ray N; Jeffrey JL; Labranche CC; Doms RW
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):13-24. PubMed ID: 20055594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
    Soriano V; Poveda E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.
    Blanpain C; Migeotte I; Lee B; Vakili J; Doranz BJ; Govaerts C; Vassart G; Doms RW; Parmentier M
    Blood; 1999 Sep; 94(6):1899-905. PubMed ID: 10477718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
    Garcia-Perez J; Rueda P; Staropoli I; Kellenberger E; Alcami J; Arenzana-Seisdedos F; Lagane B
    J Biol Chem; 2011 Feb; 286(7):4978-90. PubMed ID: 21118814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
    Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
    Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].
    Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():23-7. PubMed ID: 19133218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
    Berro R; Yasmeen A; Abrol R; Trzaskowski B; Abi-Habib S; Grunbeck A; Lascano D; Goddard WA; Klasse PJ; Sakmar TP; Moore JP
    J Virol; 2013 Jun; 87(12):6569-81. PubMed ID: 23468486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
    Demarest JF; Sparks SS; Schell K; Shibayama S; McDanal CB; Fang L; Adkison KK; Shachoy-Clark A; Piscitelli SC
    J Clin Pharmacol; 2008 Oct; 48(10):1179-88. PubMed ID: 18676693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.